Core Insights - BioCryst Pharmaceuticals announced significant real-world evidence demonstrating the effectiveness of ORLADEYO (berotralstat) in reducing hereditary angioedema (HAE) attack rates in adolescents and individuals with severe HAE over an 18-month follow-up period [1][3][7] Group 1: Study Findings - The study presented at the ISPOR 2025 conference showed that patients experienced significantly lower HAE attack rates while on ORLADEYO, with a reduction from a baseline of 7.78-8.23 attacks/month to 1.24-1.90 attacks/month [10] - Specifically, patients had 6.25 fewer attacks/month at 12 months and 6.43 fewer attacks/month at 18 months after starting ORLADEYO [10] - Adolescents aged 12-17 years also showed significant reductions, with 1.56 fewer attacks/month at 12 months and 1.85 fewer attacks/month at 18 months [10] Group 2: Patient Population - The findings were based on a retrospective pre-post study involving 56 U.S. patients with C1-inhibitor deficiency and 99 U.S. adolescents with HAE [5][6] - The results indicate that ORLADEYO is effective across different age groups and severity levels of HAE, providing confidence to both physicians and patients [3][7] Group 3: Product Information - ORLADEYO is the first and only oral therapy specifically designed for the prophylaxis of HAE attacks in patients aged 12 years and older, functioning as a plasma kallikrein inhibitor [8][9] - The therapy is administered as a once-daily capsule, which works by decreasing the activity of plasma kallikrein to prevent HAE attacks [8]

Financial Data and Key Metrics Changes - The company reported having €5 million in cash as of September 24, which is expected to provide a cash runway into the third quarter of 2026, beyond the readout of the on-demand phase three study [43]. Business Line Data and Key Metrics Changes - The company is developing ducriptaban, a novel oral bradykinin B2 receptor antagonist, for both on-demand and prophylactic treatment of hereditary angioedema (HAE) [2][4]. - Phase two data showed that ducriptaban achieved an 85% reduction in attacks compared to placebo, with over 90% reduction in moderate to severe attacks requiring rescue medication [27][30]. Market Data and Key Metrics Changes - In the U.S. market, approximately 65% of HAE patients are currently on prophylaxis, with expectations that this could increase to 70-80% with the introduction of an oral option [32]. - The European market is slower in adopting prophylactic therapies, but countries like Germany and France are expected to catch up soon [10][11]. Company Strategy and Development Direction - The company aims to provide innovative oral therapies for both on-demand and prophylactic treatment, addressing the need for convenience and efficacy in HAE management [7][14]. - The strategy includes capturing a broader patient base globally, beyond just the U.S. and Western Europe, by offering oral therapies [11]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming oral therapies penetrating the market, highlighting the significant unmet need in the HAE community [13][14]. - The company anticipates growth in both prophylactic and on-demand markets, driven by the ease of administration and efficacy of their oral product [33]. Other Important Information - The company is also exploring opportunities in acquired angioedema, which is a different patient population but shares similar physiological responses to HAE [48][49]. - The company plans to release more data regarding efficacy, safety, and quality of life from ongoing studies in 2025 [45]. Q&A Session Summary Question: What is the opportunity in acquired angioedema? - The acquired angioedema population is estimated to be about 10% on top of type one and type two HAE, with a high unmet medical need and potential for commercial opportunity [48][49]. Question: How does the company plan to manage recruitment for the acquired angioedema study? - The company is optimistic about recruitment, noting a strong desire among patients to join clinical trials due to the lack of available treatments [58].